Article
Pharmaceutical Executive
KPMG, a professional services firm providing business solutions and audit, tax, and advisory services, released its CEO Outlook survey results. The survey found that low interest rates and high stock valuations are fueling U.S. life sciences CEOs’ growing appetite for mergers and acquisitions.
Some key takeaways from the survey include:
To view the full survey, visit here.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.